Condition (MeSH)
46, XX Disorders of Sex Development
ClinicalTrials.gov lists 80 trials for 46, XX Disorders of Sex Development or a narrower condition beneath it. National Institute of Environmental Health Sciences (NIEHS) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
When did 46, XX Disorders of Sex Development trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 8 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 3 |
| 2019 | 5 |
| 2018 | 4 |
| 2017 | 2 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are 46, XX Disorders of Sex Development trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 9 |
| Phase 3 | 2 |
| Phase 4 | 9 |
| Not applicable | 25 |
| Observational | 28 |
How many 46, XX Disorders of Sex Development trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 11 |
| Enrolling by invitation | 2 |
| Completed | 36 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most 46, XX Disorders of Sex Development trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Environmental Health Sciences (NIEHS) | 2 |
| 59th Medical Wing | 1 |
| Clinique Ovo | 1 |
Which drugs are being tested for 46, XX Disorders of Sex Development? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| .spironolactone | 3 |
| Estradiol | 2 |
| Salsalate | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Metformin | 10 |
| Progesterone 8% | 3 |
| clomiphen citrate | 2 |
| Micronized Progesterone | 2 |
| Flutamide 1% gel | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do 46, XX Disorders of Sex Development trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome | 1 | 1 |
| Undisclosed Exclusion Criteria - Symptoms and History of Migraines with Aura | 1 | 1 |
Which publications cover 46, XX Disorders of Sex Development? (20)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The Effect of Psychosexual Education on Promoting Sexual Function, Genital Self-Image, and Sexual Distress among Women with Rokitansky Syndrome: A Randomized Controlled Clinical Trial. | Journal of pediatric and adolescent gynecology | 2022 | Yes |
| Donor robotic-assisted laparoscopy for uterus transplantation. | Fertility and sterility | 2022 | Yes |
| Twelve Live Births After Uterus Transplantation in the Dallas UtErus Transplant Study. | Obstetrics and gynecology | 2021 | Yes |
| Clinical pregnancy rates and experience with in vitro fertilization after uterus transplantation: Dallas Uterus Transplant Study. | American journal of obstetrics and gynecology | 2021 | Yes |
| Uterine Transplantation with Robot-assisted Uterus Retrieval from Living Donor: First Case in Brazil. | Journal of minimally invasive gynecology | 2021 | Yes |
Showing 5 of 20 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| 46,XX difference of sex development | 2982 | Exact | Orphadata Science knowledge files, Product 1 |
| 46,XX difference of sex development | 2982 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence.